I've been trying to get an idea of the answer to this myself. I am struggling because if the new money is in face institutional money I don't think it will be as weak as private investors. I dont mean that as a slant, but us private investors tend to panic sell.

I would think that strong data, and a ph3 trial might cause the institutional money to hold tight.

Also, it is my belief that strong results coupled with BP paper and a moderate amount of publicity, would cause oh 3 trials to be enrolled fairly quickly. The faster enrollment, the shorter the duration of a dip would be.